JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB263430

Human ZCCHC2 knockout A549 cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

ZCCHC2 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 29 bp deletion in exon1 and 55 bp deletion in exon1.

View Alternative Names

9930114B20Rik, AW212015, DKFZp451A185, FLJ20281, KIAA1744, MGC112793, MGC13269, TNFRSF11A, ZCHC2_HUMAN, Zinc finger CCHC domain-containing protein 2

2 Images
Sanger Sequencing - Human ZCCHC2 knockout A549 cell lysate (AB263430)
  • Sanger seq

Unknown

Sanger Sequencing - Human ZCCHC2 knockout A549 cell lysate (AB263430)

Allele-2 : 29 bp deletion in exon1

Sanger Sequencing - Human ZCCHC2 knockout A549 cell lysate (AB263430)
  • Sanger seq

Unknown

Sanger Sequencing - Human ZCCHC2 knockout A549 cell lysate (AB263430)

Allele-1 : 55 bp deletion in exon1

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 29 bp deletion in exon1 and 55 bp deletion in exon1.

Disease

Carcinoma

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab263430-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human ZCCHC2 knockout A549 cell lysate", "number":"AB263430-CMP02", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type A549 cell lysate", "number":"AB263430-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
ZCCHC2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The zinc finger CCHC domain-containing protein 2 also known as ZCCHC2 functions mechanically as an RNA-binding protein. It plays a role in RNA metabolic processes. ZCCHC2 is approximately 90 kDa in mass and includes several zinc finger motifs that are important for its interaction with RNA. It is expressed highly in the nucleus of cells across various tissues with notable levels in the brain and other central nervous system structures. This indicates its involvement in regulating RNA under specific physiological conditions.
Biological function summary

ZCCHC2 interacts with the cellular machinery involved in RNA splicing and processing. It is part of ribonucleoprotein complexes that facilitate these functions. This protein assists in modulating RNA stability and contributes to the precise processing required for mature RNA molecules. These activities are important for maintaining proper gene expression by ensuring that RNA transcripts are accurately produced and modified before translation occurs.

Pathways

ZCCHC2 plays a role in RNA processing and degradation pathways. It acts within the spliceosomal complex aiding in the proper removal of introns from pre-mRNA. ZCCHC2 interacts with other proteins such as components of the Human spliceosome which include splicing factors that orchestrate the splicing process. It also connects with pathways linked to RNA surveillance mechanisms where it helps in quality control of RNA transcripts.

ZCCHC2 has connections to neurological conditions and cancer. Abnormal expression levels or mutations in ZCCHC2 may relate to altered splicing activities leading to neurodevelopmental disorders. Additionally its dysregulation might contribute to the genesis of certain cancers through disrupted RNA processing. Proteins like spliceosomal components and RNA-binding proteins are usually involved in such diseases highlighting the importance of balanced ZCCHC2 function for cellular health.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com